AGRX Agile Therapeutics
- 1.440
- +0.010+0.70%
Agile Therapeutics News
Agile Therapeutics Analyst Ratings
Buy Rating for Agile Therapeutics: Regulatory Tailwinds and Strong Sales Growth Forecast
Analysts Are Bullish on Top Healthcare Stocks: Mainz Biomed B.V. (MYNZ), Agile Therapeutics (AGRX)
Agile Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Rallybio (RLYB), Agile Therapeutics (AGRX) and Biomea Fusion (BMEA)
HC Wainwright & Co. Reiterates Buy on Agile Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. Reiterates Buy on Agile Therapeutics, Maintains $12 Price Target
Analysts Have Conflicting Sentiments on These Healthcare Companies: Agile Therapeutics (AGRX), Check-Cap (CHEK) and Doximity (DOCS)
Maxim Group Downgrades Agile Therapeutics (AGRX) to a Hold
Maxim Group Keeps Their Buy Rating on Agile Therapeutics (AGRX)
HC Wainwright Cuts Price Target on Agile Therapeutics to $3 From $5, Maintains Buy Rating
H.C. Wainwright Sticks to Its Buy Rating for Agile Therapeutics (AGRX)
Agile Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Agile Therapeutics, Lowers Price Target to $3
Agile Therapeutics (AGRX) Gets a Buy From Maxim Group
Maxim Group Keeps Their Buy Rating on Agile Therapeutics (AGRX)
Maxim Group Reaffirms Their Buy Rating on Agile Therapeutics (AGRX)
Maxim Upgrades Agile Therapeutics to Buy from Hold, Sets $1 Price Target
Agile Therapeutics analyst ratings
Maxim Group Upgrades Agile Therapeutics to Buy, Announces $1 Price Target
Analysis
Price Target
No Data
